EPO and polycythemia: We have demonstrated that the mutation is sufficient for the development of polycythemia, increased EPO secretion, somatostatinoma-related manifestations, and immature chromaffin cell features consistent with the origins of the noradrenergic paragangliomas and pheochromocytomas characteristic of the affected patients.